S1PR1 and IL-23 inhibitor pipeline for ulcerative colitis

Behind approved ulcerative colitis therapies Zeposia from BMS and Stelara from Johnson & Johnson, eight more S1PR1 and IL-23 inhibitors are making their way through the clinic. 

Last week,  Pfizer Inc. (NYSE:PFE) reported data from two Phase III trials of S1PR1 inhibitor etrasimod that suggested the small molecule could be best in class, with remission rates generally higher than marketed therapy Zeposia ozanimod from Bristol Myers Squibb Co. (NYSE:BMY). ...